Editorial
Published on 20 Feb 2023
Editorial: Biology and treatment of high-risk CLL
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.1109950
- 3,092 views
- 1 citation
Type at least 3 characters
2,056 articles
articles
Original Research
Published on 17 Feb 2023
Multicolor flow cytometric assessment of Ki67 expression and its diagnostic value in mature B-cell neoplasms
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1108837
- 8,866 views
- 12 citations
Case Report
Published on 17 Feb 2023
Case report: Genomic analysis of a therapy-related chronic myelomonocytic leukemia with KMT2A rearrangement that progressed to acute myeloid leukemia with acute promyelocytic leukemia-like features
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1116418
- 3,795 views
Systematic Review
Published on 16 Feb 2023
Post-transplant cyclophosphamide versus anti-thymocyte globulin in allogeneic hematopoietic stem cell transplantation from unrelated donors: A systematic review and meta-analysis
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1071268
- 5,587 views
- 17 citations
Original Research
Published on 16 Feb 2023
Characterization of clonal immunoglobulin heavy V-D-J gene rearrangements in Chinese patients with chronic lymphocytic leukemia: Clinical features and molecular profiles
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1120867
- 3,277 views
- 4 citations
Original Research
Published on 16 Feb 2023
Unmanipulated haploidentical hematopoietic stem cell transplantation for pediatric de novo acute megakaryoblastic leukemia without Down syndrome in China: A single-center study
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1116205
- 3,639 views
- 8 citations
Original Research
Published on 15 Feb 2023
A diagnostic scoring model of ENKTCL in the nose-Waldeyer’s ring based on logistic regression: Differential diagnosis from DLBCL
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1065440
- 2,396 views
- 2 citations
Original Research
Published on 15 Feb 2023
Lamivudine 24-month-long prophylaxis is a safe and efficient choice for the prevention of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients with advanced DLBCL undergoing upfront R-CHOP-21
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1130899
- 3,603 views
- 6 citations
Correction
Published on 14 Feb 2023
Corrigendum: Poly(rC)-binding proteins as pleiotropic regulators in hematopoiesis and hematological malignancy
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.1132485
- 1,485 views
Review
Published on 14 Feb 2023
Measurable residual disease in chronic lymphocytic leukemia
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1112616
- 11,666 views
- 8 citations
Editorial
Published on 14 Feb 2023
Editorial: Epidemiological trends in hematological malignancies
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1151774
- 2,745 views
- 1 citation
Original Research
Published on 14 Feb 2023
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1117815
- 5,189 views
- 18 citations
Original Research
Published on 10 Feb 2023
In-depth circulating tumor DNA sequencing for prognostication and monitoring in natural killer/T-cell lymphomas
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1109715
- 4,451 views
- 12 citations
Original Research
Published on 10 Feb 2023
A novel ferroptosis-related gene signature for predicting prognosis in multiple myeloma
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.999688
- 6,617 views
- 18 citations
Opinion
Published on 09 Feb 2023
Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1106579
- 6,779 views
- 2 citations
Original Research
Published on 09 Feb 2023
Mitochondrial gene expression signature predicts prognosis of pediatric acute myeloid leukemia patients
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1109518
- 5,699 views
- 8 citations
Original Research
Published on 09 Feb 2023
High-risk multiple myeloma predicted by circulating plasma cells and its genetic characteristics
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1083053
- 4,898 views
- 14 citations
Original Research
Published on 09 Feb 2023
Risk factors for post-transplant relapse and survival in younger adult patients with t(8;21)(q22;q22) acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: A multicenter retrospective study
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1138853
- 3,905 views
- 7 citations
Review
Published on 09 Feb 2023
PTCL, NOS: An update on classification, risk-stratification, and treatment
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1101441
- 16,379 views
- 19 citations
Review
Published on 08 Feb 2023
Tyrosine kinases in nodal peripheral T-cell lymphomas
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1099943
- 4,492 views
- 8 citations
Review
Published on 07 Feb 2023
Hepatitis B virus-infection related cryoglobulinemic vasculitis. Clinical manifestations and the effect of antiviral therapy: A review of the literature
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1095780
- 8,202 views
- 10 citations
Systematic Review
Published on 07 Feb 2023
Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1098326
- 9,781 views
- 20 citations
Review
Published on 07 Feb 2023
Research progress on molecular biomarkers of acute myeloid leukemia
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1078556
- 8,857 views
- 9 citations
Mini Review
Published on 06 Feb 2023
Myeloid leukemia factor 1: A “double-edged sword” in health and disease
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1124978
- 3,853 views
- 5 citations